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boxane A, derives fro arachidonic a id, is a potent 
agonist of platelet aggregation an has vasoconstrictive 
properties (1,2). Platelet activation nd cardiac release of 
boxane undoubtedly occur during acute ischemic syn- 
dromes and coronary thrombolysis (3-7). In contrast, many 
studies slave suggested a lack of platelet activation i stable 
angina (6,8-l 1). Paradoxically, we and others have reported 
that hromboxane was released into the coronary bed during 
rapid atrial pacing in patients with stable angina pectoris, 
whereas a similar pacing in control subjects did not cause 
thromboxane r lease (1246). However, we found neither 
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yoca~di~m nor signs of platelet 
concomitant with thromboxane pro- 
duction k our patients with coronary artery disease under- 
going pacing-induced ischemia (16). These results raised the 
question of an extraplatelet source of thromboxane; l uko- 
cytes, monocytes, macrophages or resident vascular cells 
thesize thromboxane during reversible episodes of
(l&17). The use of low dose aspirin, which has 
onstrated toselectively inhibit platelet cyclooxy- 
genase, could help to dete ine the source of thromboxane 
in patients with stable angina. 
Aspirin irreversibly acetylates fDe serine residue Ser 529 
in the cyclooxygenase enzyme (18). Sustained inhibition of 
this enzyme prevents both thromboxa~e and prostacyciin 
synthesis. A selective action of aspirin on thromboxane A2
synthesis by platelets has been proposed by reducing the 
daily dose of aspirin (119). The cumulative in of low doses 
of aspirin suppresses platelet thromboxa~e synthesis for 
the lifetime of the cell, whereas prostacyclin is still produced 
by endothelial cells, which are nucleated and can resynthe- 
size new cyclooxygenase. Prostacyclin has beneficial ntiag- 
gregatory and vasodilative effects, and it has been suggested 
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that inhibition of prostacyclin production may limit the 
antithrombotic effects of aspirin (20). 
In this study, we evaluated the levels of chronic throm- 
boxane production i patients with stable angina, treated or 
not treated by very low dose aspirin (50 mg/day). We used 
low dose aspirin to test the hypothesis of a platelet (or 
extraplatelet) source of thromboxane in patients with stable 
coronary heart disease. Low doses of aspirin do not block 
the cyclooxygenase of nucleated ceils (endothelial cells, 
monocyteslmacrophages) nd preserve their biosynthesis of 
ins, which was assessed by measuring the uri- 
.dEnor-6-keto-prostaglandin 
contrast, inhibition of 
ay of aspirin was as- 
sessed using the in vitro serum throm~xan~ concentration 
originating from platelets. Subsequently, the cellular s~~~cc 
of thromboxane in patients with stable angina was deter- 
mined by the evolution of in vivo levels of thrombox~ue 
metabolites after treatment with low dose aspirin. Further- 
termined the effects of this very iow dose aspirin 
therapy on the acute release of thromboxane i to the coro- 
nary sinus plasma during pacing-induced myocardial isch- 
emia. These r sults may improve our understandin 
mechanisms of the benefits of very low dose aspirin in 
patients with stable angina nd determine th cellular o igin 
of thromboxane i  these patients. 
ts. We studied 42 patients (mean [t 
13 who abstained from drugs inhibitin 
ase for at least 10 days. All patients provided a urinary 
sample without previous hy ion. Twenty-four of these 
patients had typical effort na pectoris, underwent a 
positive xercise stress test and had ~~io~~phic~iy proved 
artery disease. As described inour previous stud- 
nts were in stable condition, with significant isch- 
segment depression after mild exercise (>i mm at 
of the age-predicted maximal heart rate) (16.21). 
of the 24 patients with stable angina, free of aspirin 
therapy for >I0 days, underwent rapid atrial pacing. Ten 
other patients with angina, who enrolled for the I-day pro- 
tocol on very low dose aspirin, underwent a rial stimulation 
on the eighth day of the protocol. Treatment compliance was 
monitored by tablet count and serum thromboxane m asure- 
t. Only 8 of these 10 patients completed the protocol. 
nts received information about he study and gave their 
writteu consent. The study protocol had been approved 
previously by the hospital’s Ethics Committee. 
To compare urinary eicosanoid levels of patients with 
coronary artery disease, we also studied 18 healthy ambula- 
tory age- and gender-matched subjects free of aspirin and 
any other cyclooxygenase-inhibiting drugs. They provided 
urinary samples under the same conditions as the patients 
with coronary heart disease. The control subjects had no 
complaints of chest pain, an each Reformed astress test, 
which was negative. 
Gents unable to void or 
urinary vo~~rne for analy- 
first day to measure total serum tbromboxa~e 
~atme~t was sta 
blood was measMr~d to reevaluate total seru 
atients were the 
States Catheter and instrument 
saline so~Mti0~ witbo~t 
atropin~ (0.5 mg) was administered intravenously. 
dynamics of metabolite r lease into tbe coronary sinus 
(16,21), three sets of blood samples were collected: at rest 
before pacing, during the last minute of pacing and immedi- 
ately after pacing was discontinued. At each measurement, 
blood samples were taken simultaneously from the aorta nd 
the coronary sinus and then placed on ice before centrifuga- 
tion. To avoid artifacts in the dynamics of thromboxane 
release, the lines were flushed frequently (test ubes con- 
tained indomethacin). A late sample was taken after ceasing 
atrial pacing to check for the absence of a continuous 
increase in thromboxane levels, which returned to baseline 
values. Simultaneous aortic and coronary sinus samples 
vide transmyocardial v lues (16). 
nrements. Plasma thromboxane Bzcon- 
centrations in patients undergoing atrial stimulation were 
measured by collecting 4 ml of blood in test tubes containing 
ethy~e~cdiami~etetr~cetic acid andindomeihacin (5 amoY 
liter and 10 pmokliter final concentrations, respectively). 
Samples were transferred to ice immediately, centr?uged at
3,000 x g for 10 min. and the plasma was stored at -70°C 
until further analysis. Thromboxane B, analyses were per- 
formed by enzyme immunoassay (23). 
To determine serum thromboxane productton by plate- 
lets, nonanticoagulated blood was allowed io clot at 37°C for 
artery disease (74.8 k 13.0 ng/fflmol f creatinine, p < 0.01 
between both groups) (Fig. 1). Thromboxane production was 
depressed by 73% in 10 patients with angina who received 
the very low dose aspirin regimen after 8 days of aspirin 
ng/mmol f creatinine, p C 0.001) (Fig. 
ow dose aspirin regimen decreased the 
excretion of thromboxane A, metabolites in patients with 
stable angina to levels imilar to those measured in control 
subjects (p = NS between groups) (Fig. I). 
Prostacyclin biosynthesis, as reflected by the urinary 
excretion of 2,3d~or-~~eto-pros~~andin Flalpha, was com- 
parable inpatients with angina nd control subjects (27.6 2 3.6 
vs. 43.3 + 15.7 ng/mmol fcreatinine, respectively, p = NS). 
The very low dose aspirin regimen did not alter pr~s~~cyc~in 
biosynthesis in patients with nary heart disease (Fig. I). 
Mywardial ischemia ndu by rapid atriai pat 
patients recruited for atrial stimulation had severe stenoses 
< Q.QOl 
ean urinary levels of I I-debydro-th~Q~boxane 
z in 24 patients with angi 
acsp, 18 healthy contrd subjects ( 
neina with very low dose aspirin ( 
urinary le\,els of 2,3-~inor-6-~eto-prostag~a~~i~ (PC+) Flalphn in the 
same palierlts. 
of the left coronary territory. Ten tients underwent right 
heart catheterization on the eighth 
col. In one patient, the coronary sinus was not cathet 
for technical reasons, and pacing was not performed inthis 
patient. In another patient, myocardial ischemia was not 
induced. Subsequently, these two patients were not consid- 
ered in the analysis of the dynamics of lactates and throm- 
2 during pacing; only eight patients completed the 
taco!, with the occurrence of significant ischemia 
during rapid atrial pacing. Seven more patients with angio- 
graphically proved isease of the left coronary territory, not 
treated by any cyclooxygenase-inhibiting drug,undereat 
atrial pacing and demonstrated significant myocardial isch- 
emia. Atrial sti~l~lat~o~ caused a significant decrease 
fractional lactate xtraction during pacing in both contr 
groups). 
na and aspirin-treated patie 
nt from baseline measurements in both 
The percent of lactate xtraction during atria1 pacing in 
patients with angina not treated by aspirin decreased sharply 
and was lower during the last minute of pacing than in 
patients following the aspirin regimen (lactate extraction was 
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baseline 
er the end of pacing (post- 
patients. “p < 0.001, Mere 
= 0.02 between groupsj 
asured immediately after 
was discontinued di significantly between the 
lactate ext~ctian was -24.7 5~ 12 
- 15.1 I 147% in patients w 
IeveIs. Baseline coronary sinus plasma 
levels of thromboxane B3measured atrest in patients with 
stable angina were higher in the control group than in the 
group with very low dose aspirin regimen (217 + 35 and 16 2 
3 &ml, respectively, p c 0.001 between groups). Pacing- 
induced ischemia was associated with the acute release of 
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tion to a ~~~~a1 level (Fig. I). A 
that arid atrial pacing, which 
acute release of both lactate an 
aspirin totally prevents the acute release of thro 
into the coronary bed during reversible ~schemic 
and normalizes the urinary excretion of tbromboxa~e m - 
tabolites but does not alter the endotbe~ial prostacychn 
biosynthesis (Fig. I). The relative biochemical selectivity of
aspirin for thromboxane AZ, when used at very low doses, 
confirms that either endothelial cells and other nucleated 
cells (monocyteslmacrophages) re spared by this low dose 
regimen or that they retain the capacity for generating ew 
cyclooxygenase enzyme to synthesize eicosanoids. Our data 
sustain the hypothesis that plasma thromboxane is released 
by platelets, not by macrophages, and thatplatelet activation 
occurs in patients with stable angina, particularly during 
ia. We and others 
have demonstrated that pacing-induced ischemia 
with stable angina is associated consistently with 
taneous and acute release ofthromboxane Bzin the coronary 
sinus (12~16,21,22). In the present study, patients who had 
pacing-induced myocardial ischemia under a very low dose 
aspirin regimen did not demonstrate increased thtomboxane 
production. It is likely that circulating levels of thromboxane 
play a minor ole in the degree of ischemia because the final 
levels of lactates were not statistically different between 
that very low dose aspi ’ reduces the level of urinary 
1 l-dehydro-thromboxane by 73% and completely pre- 
vents the acute release of thromboxane during pacing- 
induced ischemia strongly suggest that platelets are the 
source of thromboxane i  patients with angina not treated by 
aspirin. These results upport a recent study using whole- 
blood impedance aggregometry that demonstrated platelet 
activatiou across the coronary circulation during rapid atrial 
pacing of patients with stable coronary heart disease (27). 
Tachycardia c used a W;b increase inplatelet aggregation in 
the coronary sinus blood of these patients with significant 
left coronary artery disease (27). Taken together, these data 
confirm the hypothesis of platelet activation during rapid 
atrial pacing in patients with stable angina. The similarities 
between pacing- and effort-induced ischemia suggest that 
h a low dose aspirin regimen (30). 
co~ce~trat~o~ (22% with 
emonstrated the clinical benefits of 
ients with stable angina (33,3 
s with stable coronary artery 
produced much more thromboxane than healthy subjects. 
Platelets (and not macrophages) appear to be activated and 
to release thromboxane, particularly during episodes of 
pacing-induced ischemia. However, ~reve~tiou f throm- 
boxane release into the coronary bed by 
does not avoid the induction of a similar 
emia. Very low dose aspirin therapy in patient 
angina can reduce significantly chronic th 
sis, prevent acute release oftbrom~oxa~ 
episodes of ischemia nd preserve ndoth 
biosynthesis. These findings may provide the basis for 
explaining the protective clinical effects of low dose :I 
reported recently in patients with stable angina. The 
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tion of the incidence ofdose-related complications is another 
potential benefit of very low doses of aspirin. 
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